Summary
Women who are pregnant or breastfeeding are traditionally excluded from medical research due to safety concerns. As a result of this, only 5 % of medications have adequate safety information on their use in pregnant or breastfeeding women, and this makes it very hard for doctors and women to make informed decisions about their treatment. Nonetheless, some 90 % of women are exposed to a prescription medication at some point during their pregnancy.
The ultimate goal of ConcePTION is to create a trusted biomedical ecosystem capable of providing evidence-based information on the safety of medications during pregnancy and breastfeeding in an efficient, systematic and ethically responsible way. The information will be provided in a form that is usable by both healthcare providers and patients alike.
The project will achieve this in a number of ways. Firstly, it will improve and unify existing approaches to data collection in this area by re-using existing, de-identified data generated during routine patient care. The project also aims to deliver procedures and tools for the collection of digital data and samples directly from pregnant women.
They will also create the first Europe-wide breast milk biobank for research purposes, and develop tools to predict which drugs are likely to be transferred to breast milk. Finally, the team will establish a web-based drug information knowledge bank.
Achievements & News
May 2024
Transitioning from an IMI or IHI project to a non-profit association is one way to ensure the sustainability of project...
May 2022
Pregnancy should be a time of joy and excitement, although inevitably it is also one of apprehension and concern. Mothers...
August 2021
Studies of medicines safety and breastfeeding often involve animals. Now IMI’s CONCEPTION project has a plan that could deliver better...
Studies of medicines safety and breastfeeding often involve animals. Now IMI’s CONCEPTION project has a plan that could deliver better results while also using fewer animals.###
One of the aims of the CONCEPTION project is to deliver knowledge, tools and resources so that breastfeeding women and their doctors can take an informed decision about whether or not it is safe to breastfeed while taking a given medication. As part of this effort, the project is collecting samples of milk from breastfeeding women. However, on its own, this is not enough, and so the project is investigating other ways of studying which medicines are likely to make it into breast milk.
Currently, three types of models are used to help answer this question. In vitro models consist of cells in a dish or test tube, while in silico models are computer based. CONCEPTION is working to improve in vitro and in silico models. Finally, there are animal (in vivo) models, which are useful for analysing the mechanics of how a medicine makes it into the breast milk. CONCEPTION researchers recently published an extensive review of the pros and cons of different animals as models for research on breastfeeding.
Ultimately, the CONCEPTION team believes that the best way of studying which medicines get into breast milk is to combine in vivo, in vitro and in silico models.
How would combining approaches work in practice? ‘The approaches used are directly connected through a continuous flow of information,’ explains Alberto Elmi of the University of Bologna. ‘Moreover, both in vitro and in vivo data feed the mathematical approaches of the in silico platform, and this will further strengthen the other models. In addition, use of the human lactation data collected elsewhere in the project will allow us to validate the in silico, in vivo and in vitro platforms.’
Find out more
- Read the article in full
The EHDEN and ConcePTION projects plus the ADVANCE/VAC4EU initiative will help the European Medicines Agency (EMA) gather real world data on COVID-19 vaccines and treatments once they are approved and being used in day-to-day clinical practice.###
EHDEN is already working with 25 data partners across Europe, to help them map COVID-19 data to a common data model. Now, it is set to collaborate with the EMA on the creation of a framework for multicentre cohort studies on the use of medicines in COVID-19 patients.
ConcePTION will collaborate with the EMA on a project that will collect data on the impact of COVID-19 in pregnancy and follow up the baby to monitor long-term outcomes in order to guide decision-making about vaccine indications, vaccination policies and treatment options for COVID-19 in pregnant women.
The international association VAC4EU (Vaccine Monitoring Collaboration for Europe) is set to work with the EMA to prepare for the monitoring of the benefits and risks of COVID-19 vaccines in Europe. VAC4EU was born out of IMI’s ADVANCE project.
‘The inclusion of EHDEN, ConcePTION and VAC4EU in the EMA’s work is testament not only to their scientific excellence but to their ability to adapt to the challenges posed by the COVID-19 pandemic,’ said IMI Executive Director Pierre Meulien. ‘I am confident that the projects will make a valuable contribution to this important initiative which is a key part of the global fight against the disease.’
The outcomes of the projects will feed into the work of EMA’s COVID-19 EMA pandemic Task Force (COVID-ETF) and EMA’s scientific committees, to ensure that the evidence is translated into scientific opinions on the optimal use of the medicines and vaccines concerned.
Find out more
Evidence suggests that up to 95 % of the five million women who get pregnant in the EU every year will reach for a prescription drug at some point. And yet, only about 5 % of the medication they take comes with pregnancy and breast-feeding-related safety information. Now, IMI’s ConcePTION project is working to fill the data gap. ###As a first step, they are running a survey to gather as much information as possible about how women who are pregnant or breastfeeding are currently making choices about medication.
Elsewhere, the project aims to establish new and better ways to collect digital data and samples; create a Europe-wide breast milk biobank for research; develop tools to predict transferability of drugs medicines into breastmilk; and build a web-based drug info bank, presented in a way that women have a reliable single source and don’t need a medical degree to understand.
Participants
Show participants on mapEFPIA companies
- Abbvie Inc, North Chicago, Illinois, United States
- Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- Ellegaard Gottingen Minipigs As, Dalmose, Denmark
- Glaxosmithkline Research & Development Limited, Brentford, Middlesex, United Kingdom
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Labcorp Early Development Laboratories Limited, Harrogate, United Kingdom
- Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
- Novartis Pharma AG, Basel, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Pfizer Limited, Sandwich, Kent , United Kingdom
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
- Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), Switzerland
- Teva Pharmaceutical Industries Limited, Netanya, Israel
- UCB Biopharma, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Agenzia Regionale Di Sanita, Firenze, Italy
- Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
- Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric), Graz, Austria
- Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- Consiglio Nazionale Delle Ricerche, Roma, Italy
- European Forum For Good Clinical Practice, Brussels, Belgium
- European Institute Of Women'S Health Company Limited By Guarantee, Dublin, Ireland
- Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
- Institut National De La Sante Et De La Recherche Medicale, Paris, France
- Karolinska Institutet, Stockholm, Sweden
- Katholieke Universiteit Leuven, Leuven, Belgium
- Medicines And Healthcare Products Regulatory Agency, London, United Kingdom
- Region Stockholm, Stockholm, Sweden
- Region Uppsala, Uppsala, Sweden
- Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
- St George'S Hospital Medical School, London, United Kingdom
- Stichting Entis (European Network Teratology Information Services) Foundation, Hertogenbosch, Netherlands
- Stichting Lareb, 's Hertogenbosch, Netherlands
- Swansea University, Swansea, United Kingdom
- Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland
- The European Institute For Innovation Through Health Data, Gent, Belgium
- The European Medicines Agency, Canary Wharf, London, United Kingdom
- The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom
- The University Of Manchester, Manchester, United Kingdom
- Universita Degli Studi Di Ferrara, Ferrara, Italy
- Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
- Universitetet I Oslo, Oslo, Norway
- University Of Kwazulu-Natal, Westville, South Africa
- University Of Ulster, Coleraine, United Kingdom
- Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Bionotus, Temse, Belgium
- Elevate BV, Utrecht, Netherlands
- Orcion BV, Asten, Netherlands
- The Synergist, Bruxelles, Belgium
Third parties
- Masarykova univerzita, Brno, Czech Republic
- Medizinische Universitat Graz, Graz, Austria
- Ministry Of Health, Jerusalem, Israel
- Nearshore Macedonia LTD Skopje, Skopje, North Macedonia
- Shamir Health Corporation, Zrifin, Israel
- Synergist Services, Bruxelles, Belgium
- Universitaet Leipzig, Leipzig, Germany
Participants | |
---|---|
Name | EU funding in € |
Academisch Ziekenhuis Groningen | 260 939 |
Agenzia Regionale Di Sanita | 359 110 |
Alma Mater Studiorum - Universita Di Bologna | 832 760 |
Biobanks And Biomolecular Resources Research Infrastructure Consortium (Bbmri-Eric) | 201 000 |
Bionotus | 676 038 |
Centre Hospitalier Universitaire De Toulouse | 912 929 |
Centre Hospitalier Universitaire Vaudois | 482 806 |
Consiglio Nazionale Delle Ricerche | 143 223 |
Elevate BV | 110 919 |
European Forum For Good Clinical Practice | 71 648 |
European Institute Of Women'S Health Company Limited By Guarantee | 135 160 |
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana | 89 869 |
Institut National De La Sante Et De La Recherche Medicale | 60 721 |
Karolinska Institutet | 10 267 |
Katholieke Universiteit Leuven | 1 062 746 |
Medicines And Healthcare Products Regulatory Agency | 60 597 |
Orcion BV | 94 126 |
Region Stockholm | 119 911 |
Region Uppsala | 96 896 |
Rijksinstituut Voor Volksgezondheid En Milieu | 107 321 |
St George'S Hospital Medical School | 370 324 |
Stichting Entis (European Network Teratology Information Services) Foundation | 211 897 |
Stichting Lareb | 866 023 |
Swansea University | 187 844 |
Terveyden Ja Hyvinvoinnin Laitos | 283 161 |
The European Institute For Innovation Through Health Data | 446 011 |
The European Medicines Agency | 33 158 |
The Newcastle Upon Tyne Hospitals Nhs Foundation Trust | 578 695 |
The Synergist | 137 421 |
The University Of Manchester | 390 398 |
Ttopstart BV (left the project) | 41 638 |
Universita Degli Studi Di Ferrara | 238 532 |
Universitair Medisch Centrum Utrecht | 2 486 436 |
Universitetet I Oslo | 806 665 |
University Of Kwazulu-Natal | 122 638 |
University Of Ulster | 692 410 |
Uppsala Universitet | 894 281 |
Third parties | |
Name | Funding in € |
Hospices Civils De Lyon (left the project) | 10 644 |
Masarykova univerzita | 42 420 |
Medizinische Universitat Graz | 60 000 |
Ministry Of Health | 39 505 |
Nearshore Macedonia LTD Skopje | 141 188 |
Shamir Health Corporation | 131 684 |
Srebrnjak Children's Hospital (left the project) | 5 720 |
Synergist Services | 167 312 |
Universitaet Leipzig | 25 000 |
Total Cost | 15 299 991 |